Drug
Talazoparib clinical trials
Also written BMN 673, Talzenna and MDV3800.
- studies test it
- 93
- open now
- 23
- in phase 3
- 3
- first study started
- 2010
Keep track of what changes. Save the talazoparib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
93 studies that test it; most in 2021 (20)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 2 |
| 2013 | 3 |
| 2014 | 4 |
| 2015 | 7 |
| 2016 | 11 |
| 2017 | 5 |
| 2018 | 4 |
| 2019 | 10 |
| 2020 | 11 |
| 2021 | 20 |
| 2022 | 7 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 43
- Phase 2
- 61
- Phase 3
- 3
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 24 · Other 69
Pfizer (20) · National Cancer Institute (NCI) (10) · M.D. Anderson Cancer Center (5) · Massachusetts General Hospital (3) · Memorial Sloan Kettering Cancer Center (3) · Peter MacCallum Cancer Centre, Australia (3) · Dana-Farber Cancer Institute (2) · Roswell Park Cancer Institute (2)
Often tested with
Tested in the same studies.
Avelumab (6) · Temozolomide (5) · Enzalutamide (5) · Trastuzumab (5) · Atezolizumab (5) · Nivolumab (5) · Abemaciclib (5) · Axitinib (4)
Studies
Open first, then newest update. How each study uses talazoparib is read from its arms, and is right about nine times in ten.
Testing it · 93
- Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate CancerRecruitingPhase 2M.D. Anderson Cancer CenterNCT05873192Written as Talazoparib
- Talazoparib Plus Enzalutamide After Progression to Prior ARPi in Metastatic Prostate CancerRecruitingPhase 2Fundacion OncosurNCT06582628Written as Enzalutamide capsule and Talazoparib capsule
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingPhase 2American Society of Clinical OncologyNCT02693535Written as Talazoparib (CLOSED TO ENROLLMENT)
- A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or DarolutamideRecruitingPhase 2Prostate Cancer Clinical Trials ConsortiumNCT06844383Written as Talazoparib with enzalutamide
- ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian CancerRecruitingPhase 2Alexander B Olawaiye, MDNCT05071937Written as Talazoparib
- Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing SarcomaRecruitingPhase 1/2St. Jude Children's Research HospitalNCT04901702Written as Talazoparib
- Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical TrialRecruitingPhase 2Massachusetts General HospitalNCT03990896Written as Talazoparib
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Written as Talazoparib plus Irinotecan
- Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal CancerRecruitingPhase 1Roswell Park Cancer InstituteNCT04511039Written as Talazoparib Tosylate
- Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and EfficacyRecruitingPhase 1Norman J. LacayoNCT05101551Written as Talazoparib
- A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerRecruitingPhase 1/2Alliance Foundation Trials, LLC.NCT04486352Written as Talazoparib
- Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic CancersRecruitingPhase 1M.D. Anderson Cancer CenterNCT03968406Written as Talazoparib
- Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate CancerRecruitingPhase 2City of Hope Medical CenterNCT04734730Written as Talazoparib
- TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial CarcinomaRecruitingPhase 2Centre Francois BaclesseNCT04678362Written as Talazoparib + Avelumab
- Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)RecruitingPhase 1/2National University Hospital, SingaporeNCT05035745Written as Talazoparib
- Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant DeficiencyRecruitingPhase 2Seoul National University HospitalNCT04892693Written as Talazoparib Oral Capsule
- FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) TestRecruitingPhase 2Erasmus Medical CenterNCT06193525Written as Talazoparib
- PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine TumoursRecruitingPhase 1Peter MacCallum Cancer Centre, AustraliaNCT05053854Written as Talazoparib
- Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 InhibitionRecruitingPhase 1Fox Chase Cancer CenterNCT06218628Written as Talazoparib
- Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid LeukemiaNot yet recruitingPhase 1/2German Cancer Research CenterNCT05319249Written as Talazoparib 1 MG [Talzenna]
See all 93 studies that test talazoparib →
Given in every arm · 9 — talazoparib is usual care beside what is tested
- Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom TrialRecruitingPhase 1M.D. Anderson Cancer CenterNCT04693468Written as Talazoparib Tosylate
- Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingActive, not recruitingPhase 3PfizerNCT05059522Written as Talazoparib
- Talazoparib for Cohesin-Mutated AML and MDS With Excess BlastsActive, not recruitingPhase 1Dana-Farber Cancer InstituteNCT03974217Written as Talazoparib
- A Study of ART4215 for the Treatment of Advanced or Metastatic Solid TumorsCompletedPhase 1Artios Pharma LtdNCT04991480Written as Talazoparib
- Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCCWithdrawnPhase 2M.D. Anderson Cancer CenterNCT06762808Written as Talazoparib
- A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid TumorsCompletedPhase 1PfizerNCT04672460Written as TALZENNA capsule
- PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid TumorsCompletedPhase 1Jonsson Comprehensive Cancer CenterNCT02049593Written as PARP inhibitor BMN-673
- Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid MalignanciesCompletedPhase 1St. Jude Children's Research HospitalNCT02392793Written as Talazoparib
- A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal CancerWithdrawnPhase 2PfizerNCT02836028Written as Talazoparib
Codes
What other systems call talazoparib · ClinicalTrials.gg INT006432
- MeSH (NLM) C586365talazoparibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 9QHX048FRVTALAZOPARIBConfirmed FDA, NLM, Wikidata
- RxNorm 2099704Confirmed FDA, Wikidata
- Wikidata Q25100990talazoparibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C95733TalazoparibOne source FDA
- DrugBank DB11760One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C586365 | talazoparib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 9QHX048FRV | TALAZOPARIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2099704 | — | Confirmed FDA, Wikidata |
| Wikidata | Q25100990 | talazoparib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C95733 | Talazoparib | One source FDA |
| DrugBank | DB11760 | — | One source Wikidata |
Also registered as talazoparib tosylate (UNII 02WK9U5NZC · RxNorm 2099703).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.